Real-world survival benefit of treatment with sipuleucel-T

So there are new, interesting data regarding the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) with sipuleucel-T (Provenge) as well as either or both of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) — known generically as androgen-receptor signaling pathway inhibitors or ASPIs. … READ MORE …

Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Immunotherapy for men on active surveillance?

So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one: … READ MORE …

Can Provenge come back from the moribund?

It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …

Can a “new Dendreon” re-make Provenge?

At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …

Why do African Americans do better on Provenge than whites?

In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … … READ MORE …

Another new owner for Provenge

According to a media release issued rather quietly a week ago, a large Chinese conglomerate has now bought Provenge (sipuleucel-T) from Valeant, which had acquired it when Valeant bought Dendreon. … READ MORE …

Immunotherapy for the treatment of prostate cancer

The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …

The current role of sipuleucel-T in the management of advanced prostate cancer

A new review article has provided a detailed update on the current state of knowledge about the use of sipuleucel-T (Provenge®) in the treatment of advanced forms of prostate cancer. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

Does sequencing of therapy affect outcomes of treatment with sipuleucel-T + ADT in high-risk disease?

We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with high-risk prostate cancer. … READ MORE …

Court clears acquisition of Dendreon by Valeant

After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain available to prostate cancer patients. Whether Valeant will actually invest in the further development of sipuleucel-T is unknown at this time.

Valeant to acquire assets of Dendreon

According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there were no other qualified bidders that sought to compete with Valeant for these assets. Court approval of the sale will be sought on February 20.

What is going to happen to Dendreon and Provenge?

According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that sipuleucel-T (Provenge) will almost certainly continue to be available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

NICE rejects Dendreon’s Provenge … again

According to a report on the PharmaFile web site, the National Institute for Health and Care Excellence (NICE) in England has rejected Dendreon’s application for coverage of the costs of treatment with sipuleucel-T (Provenge) for the second time in less than a year. … READ MORE …